The recently passed Inflation Reduction Act (IRA) allows the Medicare program to negotiate drug prices for the first time in program history. Importantly, the process of setting prices will include a review of comparative effectiveness evidence, which is part of a broader US trend to rely increasingly on this type of analysis. Understanding the implications of these changes for the evolving value ecosystem is critical for evidence strategy and R&D investment decision-making.

In this presentation, Avalere Health experts will discuss how value and evidence strategies and investment decision-making need to evolve in an post-IRA world.

Learning objectives:

• How IRA drug pricing negotiation provisions will change the value landscape
• The impacts of IRA on R&D investment decision-making
• How data can be leveraged to improve value positioning in a post-IRA world